Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Open accessThe DOI matches its Crossref record; 486 of the 486 references it cites were found in a registry or an index.
Abstract
Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression. Immunotherapy aims to reactivate antitumor immune cells and overcome the immune escape mechanisms of tumors. Represented by immune checkpoint blockade and adoptive cell transfer, tumor immunotherapy has seen tremendous success in the clinic, with the capability to induce long-term regression of some tumors that are refractory to all other treatments. Among them, immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors (nivolumab) and CTLA-4 inhibitors (ipilimumab), has shown encouraging therapeutic effects in the treatment of various malignant tumors, such as non-small cell lung cancer (NSCLC) and melanoma. In addition, with the advent of CAR-T, CAR-M and other novel immunotherapy methods, immunotherapy has entered a new era. At present, evidence indicates that the combination of multiple immunotherapy methods may be one way to improve the therapeutic effect. However, the overall clinical response rate of tumor immunotherapy still needs improvement, which warrants the development of novel therapeutic designs as well as the discovery of biomarkers that can guide the prescription of these agents. Learning from the past success and failure of both clinical and basic research is critical for the rational design of studies in the future. In this article, we describe the efforts to manipulate the immune system against cancer and discuss different targets and cell types that can be exploited to promote the antitumor immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 401–486 of 486
Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes
Buonavista, N., Balzano, C., Pontarotti, P., Paslier, D. L., & Golstein, P. (1992) · Genomics · doi:10.1016/0888-7543(92)90169-s · Cited by 37
Margolin, K. A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1495 · Cited by 37
High CTLA-4 expression correlates with poor prognosis in thymoma patients
Santoni, G., Amantini, C., Morelli, M. B., Tomassoni, D., Santoni, M., Marinelli, O., Nabissi, M., Cardinali, C., Paolucci, V., Torniai, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24645 · Cited by 37
Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma
Powles, T., & Morrison, L. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0056-3 · Cited by 37
LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy
Friedman, L. A., Ring, K. L., & Mills, A. M. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000608 · Cited by 37
Karabon, L., Partyka, A., Ciszak, L., Pawlak, E., Tomkiewicz, A., Bojarska-Junak, A. A., Roliński, J., Wołowiec, D., Wróbel, T., Frydecka, I., et al. (2020) · Journal of Immunology Research · doi:10.1155/2020/6545921 · Cited by 37
Liu, Y., Wang, Z., Yu, F. D., Li, M., Zhu, H., Wang, K., Meng, M., & Zhao, W. G. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s273883 · Cited by 37
Antonio Lopez-beltran, B., López‐Ríos, F., Montironi, R., Wildsmith, S., & Eckstein, M. (2021) · Cancers · doi:10.3390/cancers13061424 · Cited by 37
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 37
CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
Sun, J., Chen, Y., Lubben, B., Adebayo, O., Muz, B., & Azab, A. K. (2021) · Leukemia Research Reports · doi:10.1016/j.lrr.2021.100268 · Cited by 37
Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy
Salinas, R. D., Durgin, J. S., & O’Rourke, D. M. (2020) · CNS Drugs · doi:10.1007/s40263-019-00687-3 · Cited by 36
CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Gautron, A., Bachelot, L., Aubry, M., Leclerc, D., Quéméner, A. M., Corre, S., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013466 · Cited by 36
PD-1 blockade prevents the progression of oral carcinogenesis
Dong, Y., Wang, Z., Mao, F., Cai, L., Dan, H., Jiang, L., Zeng, X. Y., Li, T., Zhou, Y. J., & Chen, Q. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab035 · Cited by 36
Gospel of malignant Glioma: Oncolytic virus therapy
Li, J., Meng, Q., Zhou, X., Zhao, H., Wang, K., Niu, H., & Wang, Y. (2022) · Gene · doi:10.1016/j.gene.2022.146217 · Cited by 36
Phua, K. K. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/680620 · Cited by 35
Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes
Jones, B. E., Maerz, M. D., Bahnson, H. T., Somasundaram, A., McCarthy, L. H., Speake, C., & Buckner, J. H. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100850 · Cited by 35
PD-1 immunobiology in glomerulonephritis and renal cell carcinoma
Curran, C. S., & Kopp, J. B. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02257-6 · Cited by 33
LAG-3 and PD-1 blockade raises the bar for melanoma
Robert, C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00276-8 · Cited by 33
A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
Lin, F., Xiong, M., Wei, H., Song, Y., Liu, R., Yang, Y., Yuan, X., Fan, D., Zhang, Y., Hao, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615534 · Cited by 32
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Tobin, J. W. D., Bednarska, K., Campbell, A., & Keane, C. (2021) · Cells · doi:10.3390/cells10051152 · Cited by 32
Olivares-Hernández, A., del Barco, E., Pérez, C. P., Miramontes‐González, J. P., Figuero-Pérez, L., Gómez, T. M., Cornejo, R. A. E., Hernández, L. B., González‐Sarmiento, R., Cruz, J. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020360 · Cited by 32
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines
Menez-Jamet, J., Gallou, C., Rougeot, A., & Kosmatopoulos, K. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.15 · Cited by 31
Shi, J., Li, M., & Yang, R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0107 · Cited by 31
Liu, L., Liu, Y., Xia, Y., Wang, G., Zhang, X., Zhang, H., Xu, Y. Y., Yuan, Y., Liu, S., & Wang, Y. (2021) · Journal of Cancer · doi:10.7150/jca.62123 · Cited by 31
Prospects for NK Cell Therapy of Sarcoma
Lachota, M., Vincenti, M., Winiarska, M., Boye, K., Zagożdżon, R., & Malmberg, K. (2020) · Cancers · doi:10.3390/cancers12123719 · Cited by 29
FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
Lv, Z., Cui, B., Huang, X., Feng, H., Wang, T., Wang, H.-F., Xuan, Y., Li, H., Ma, X., Huang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756843 · Cited by 29
Personalized tumor vaccines keep cancer in check
Kaiser, J. (2017) · Science · doi:10.1126/science.356.6334.122 · Cited by 28
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
Pol, J. G., & Kroemer, G. (2018) · Cell Research · doi:10.1038/s41422-018-0031-9 · Cited by 28
The Effect of Immunosuppressive Drugs on MDSCs in Transplantation
Yang, F., Li, Y., Zhang, Q., Tan, L., Peng, L., & Zhao, Y. X. (2018) · Journal of Immunology Research · doi:10.1155/2018/5414808 · Cited by 28
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
Normann, M., Türzer, M., Diep, L. M., Oldenburg, J., Gajdzik, B., Solheim, O., & Rud, E. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e56 · Cited by 28
Significance of KIR like natural killer cell receptors in autoimmune disorders
Agrawal, S., & Prakash, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108449 · Cited by 28
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy
Wellhausen, N., Agarwal, S., Rommel, P. C., Gill, S. I., & June, C. H. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.10.008 · Cited by 28
Girardi, D. M., Niglio, S. A., Mortazavi, A., Nadal, R., Lara, P. N., Pal, S. K., Saraiya, B., Cordes, L., Ley, L., Ortiz, O. S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3726 · Cited by 28
Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy
Klepsch, V., Pommermayr, M., Humer, D., Brigo, N., Hermann‐Kleiter, N., & Baier, G. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-019-0454-z · Cited by 27
The Paradoxical Roles of Inflammation during PD-1 Blockade in Cancer
Hill, M., Segovia, M., Russo, S., Girotti, M. R., & Rabinovich, G. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.003 · Cited by 27
Hwang, H. J., Lee, J. J., Kang, S. H., Suh, J. K., Choi, E. S., Jang, S., Hwang, S., Koh, K., Im, H. J., & Kim, N. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.390 · Cited by 27
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
Blaeschke, F., Stenger, D., Apfelbeck, A., Cadilha, B. L., Benmebarek, M.-R., Mahdawi, J., Ortner, E., Lepenies, M., Habjan, N., Rataj, F., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00499-z · Cited by 27
Emerging targets for anticancer vaccination: PD-1
Tobias, J., Steinberger, P., Drinić, M., & Wiedermann, U. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100278 · Cited by 26
CAR-T failure: beyond antigen loss and T cells
Strati, P., & Neelapu, S. S. (2021) · Blood · doi:10.1182/blood.2020010462 · Cited by 25
Immunoengineering approaches for cytokine therapy
Mansurov, A., Lauterbach, A. L., Budina, E., Alpar, A. T., Hubbell, J. A., & Ishihara, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00515.2020 · Cited by 25
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
Russo, G. L., Facchinetti, F., Tiseo, M., Garassino, M. C., & Ferrara, R. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00908-9 · Cited by 24
CD39: the potential target in small cell lung cancer
Chen, S., Wu, S., Zhang, L., Zhang, W., Liu, Y., Chen, B., Zhao, S., Li, W., Sun, C., Wang, L., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-798 · Cited by 24
Halmos, B., Burke, T. A., Kalyvas, C., Vandormael, K., Frederickson, A. M., & Piperdi, B. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.020 · Cited by 24
Mosińska, P., Gabryelska, A., Zasada, M., & Fichna, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00126 · Cited by 23
Wang, H., Shan, Q., Guo, J., Han, X., Zhao, C., Li, H., & Wang, Z. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.006 · Cited by 23
Production of Human CRISPR-Engineered CAR-T Cells
Agarwal, S., Wellhausen, N., Levine, B. L., & June, C. H. (2021) · Journal of Visualized Experiments · doi:10.3791/62299 · Cited by 23
Popp, F., Capino, I., Bartels, J., Damanakis, A. I., Li, J., Datta, R. R., Löser, H., Zhao, Y., Quaas, A., Lohneis, P., et al. (2021) · Cancers · doi:10.3390/cancers13112689 · Cited by 23
Zhu, G., Zhang, Q., Zhang, J., & Liu, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.661606 · Cited by 23
Geng, Y., Su, S., Cao, L. H., Yang, T., Ouyang, W., Liu, L., Wu, B., Zhang, Q., Lü, B., & Wang, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s350112 · Cited by 22
Eckardt, J., Schroeder, C., Martus, P., Armeanu–Ebinger, S., Kelemen, O., Gschwind, A., Bonzheim, I., Eigentler, T., Amaral, T. M. S., Ossowski, S., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03939-w · Cited by 22
Wang, Y., Cao, K., Guo, E., Mao, X., An, C., Guo, L., Zhang, C., Guo, J., Yang, X., Sun, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03071-7 · Cited by 21
Whooley, J., Alazzawi, M., Donlon, N. E., Bolger, J. C., & Robb, W. B. (2021) · Diseases of the Esophagus · doi:10.1093/dote/doab063 · Cited by 21
Gooneratne, S. L., Kent, S. J., & Parsons, M. S. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12752 · Cited by 20
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab
Heine, A., Kristiansen, G., Schild, H. H., & Brossart, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw243 · Cited by 20
Metastatic Breast Cancer: TIL it is Too Late
Savas, P. S., & Loi, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3490 · Cited by 20
Targeting the IDO-BCL2A1-Cytochrome c Pathway Promotes Apoptosis in Oral Squamous Cell Carcinoma
Zheng, Q., Gan, G., Gao, X., Luo, Q., & Chen, F. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s288692 · Cited by 20
High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
Mohamed, A., Jiang, R., Philip, P. A., Diab, M., Behera, M., Wu, C. S.-Y., Alese, O. B., Shaib, W. L., Gaines, T. M., Balch, G. C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755113 · Cited by 20
Driving an improved CAR for cancer immunotherapy
Huang, X., & Yang, Y. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88959 · Cited by 18
Xu, X., Jin, Z., Liu, Y., Gong, H., Sun, Q., Zhang, W., & Zhao, L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.013 · Cited by 18
Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells
Godlewski, J. A., Farhath, M. M., Ricklefs, F. L., Passaro, C., Kiel, K., Nakashima, H., Chiocca, E. A., & Bronisz, A. (2021) · Cancers · doi:10.3390/cancers13061287 · Cited by 18
Adaptive T cell immunotherapy in cancer
Ti, D., Bai, M., Li, X., Wei, J., Chen, D., Wu, Z., Wang, Y., & Han, W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1713-9 · Cited by 17
CAR NK Cell Therapy for T Follicular Helper Cells
King, C. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100009 · Cited by 16
Macrophage Therapy of Cancer Metastasis
Fidler, I. J. (2007) · Novartis Foundation symposium · doi:10.1002/9780470513736.ch12 · Cited by 15
Adeel, K., Fergusson, N., Shorr, R., Atkins, H. L., & Hay, K. A. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01588-7 · Cited by 15
Lo, A. A., Wallace, A., Oreper, D., Lounsbury, N., Havnar, C. A., Pechuan-Jorge, X., Wu, T. D., Bourgon, R., Jones, R., Krogh, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003001 · Cited by 15
Chen, P., Wang, H., Zhao, L., Guo, H., Zhang, L., Zhang, W., Sun, C., Zhao, S., Li, W., Zhu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713853 · Cited by 15
Zhou, C., Jiang, T., Xiao, Y., Wang, Q., Zeng, Z., Cai, P., Zhao, Y., Zhao, Z., Wu, D., Lin, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.784336 · Cited by 15
Zoine, J. T., Prince, C. Z., Story, J. Y., Branella, G. M., Lytle, A. M., Fedanov, A., Alexander, J. S., Porter, C. C., Doering, C. B., Spencer, H. T., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00283-5 · Cited by 14
Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers
Chen, P. A., You, L., & Lü, Y. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0001 · Cited by 13
Identification of CTLA-4-Positive Cells in the Human Tonsil
Tiemann, M., Atiakshin, D., Samoilova, V. E., & Buchwalow, I. (2021) · Cells · doi:10.3390/cells10051027 · Cited by 13
Furness, A. J. S., Quezada, S. A., & Peggs, K. S. (2016) · Immunotherapy · doi:10.2217/imt-2016-0064 · Cited by 12
Wang, W., Yang, X., Guo, M., Pan, Z., Shang, M., Qiu, M.-J., Wu, J., Jia, J., Ying-liang, L., Wen-ting, Z., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.03.007 · Cited by 12
Svedman, F. C., Jalsenius, M., Höiom, V., Grozman, V., Bergqvist, M., Söderdahl, F., Eriksson, H., Rotstein, S., Ny, L., Ascierto, P. A., et al. (2022) · Cancers · doi:10.3390/cancers14030702 · Cited by 12
Melenhorst, J. J., & Barrett, A. J. (2010) · Cytotherapy · doi:10.3109/14653249.2010.530649 · Cited by 11
Manzanares-Martín, B., Cebrián, A., del Puerto‐Nevado, L., Manzanares, R. G., Solanes, S., Gómez‐España, M. A., García‐Foncillas, J., & Aranda, E. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001705 · Cited by 11
Wang, J., Zhang, H., Yin, X., & Bian, Y. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13618 · Cited by 11
MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech
Cioccarelli, C., & Molon, B. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac025 · Cited by 11
Albuquerque, A., da Silva, H. C., Sartori, G., & da Silva, J. H. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1885492 · Cited by 9
Reduced KIR2DL1 Recognition of MHC Class I Molecules Presenting Phosphorylated Peptides
Betser-Cohen, G., Katz, G., Gonen‐Gross, T., Stern‐Ginossar, N., Arnon, T. I., Achdout, H., Gazit, R., & Mandelboim, O. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6762 · Cited by 8
Cut-price CAR-T cell therapies top India’s biotech agenda
Jayaraman, K. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0346-1 · Cited by 8
Guo, X., Li, S., Tong, H., Zhang, Y., Ji, Y., Zhuang, R., Zhang, C., You, Y., Lu, W., & Zhou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.802074 · Cited by 8
Gunjur, A., Chong, G., Lim, A. Y. L., Lau, E. W. F., Mitchell, P. L. R., John, T., & Arulananda, S. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.014 · Cited by 6
Un tour d’horizon du développement de biomarqueurs pour les anticorps PD-1 et PD-L1 en cancérologie
Chaput, L., & Jordheim, L. P. (2021) · Therapies · doi:10.1016/j.therap.2021.06.005 · Cited by 4
PD ‐1 inhibitors in metastatic colorectal cancer
Henry, L., Nguyen, N. D., Asokan, G. P., Hoh, S. M., & Gandhi, J. (2021) · ANZ Journal of Surgery · doi:10.1111/ans.16878 · Cited by 3
Pochon, C., Courbon, C., Bay, J., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.10.004 · Cited by 2
Assi, T., & Mir, O. (2022) · Immunotherapy · doi:10.2217/imt-2021-0297 · Cited by 2
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Metadata
- Authors
- Wang, D.-R., Wu, X.-L., & Sun, Y.-L.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2022-09-19
- Volume
- 7
- Issue
- 1
- Pages
- 331-331
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4296373959
- Cited by
- 501
- References
- 486
- FWCI
- 37.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.